Business

Two Dozen-Plus Biotechs Went Public This Year—With More In The Works

Forbes · October 14, 2026 at 9:00 AM

Two Dozen-Plus Biotechs Went Public This Year—With More In The Works

In this week’s edition of InnovationRx, the bumper crop of biotech IPOs, Isomorphic’s reported $40 billion valuation fundraise, and the impact of drugmakers’ gifts to doctors.

Read the full article on Forbes ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.forbes.com — the content belongs to Forbes.

Two Dozen-Plus Biotechs Went Public This Year—With More In The Works

More from Forbes

Social Security COLA 2027: Your Check Will Go Up 3.6%, But Cuts Could Come By 2032

Romance Scams Have Cost Americans Billions—This Journalist Went Undercover To Expose Them

Katie Zacharia May Have Committed A ‘Crime’ By Claiming She’s A Lawyer, Complaint Suggests

Many Humanities Majors Shun Internships–But Not At This College

More in Business

CoreWeave shares tumble as bond yields near 15% on concern about AI borrowing binge

Your Social Security check will rise an average of $75 a month — will it be able to keep up with inflation?

Social Security COLA 2027: Your Check Will Go Up 3.6%, But Cuts Could Come By 2032

Iran says it’s ‘counting the moments’ until it can strike U.S. warships; Saudi Aramco facilities attacked

I thought Napa was the gold standard for wine trips. Then, a city in Washington changed what I look for in a vacation.

Everything we know about the suspected plague case in Russia so far